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The chemotherapy combination of cisplatin and dichloromethotrexate was administered 
to 14 patients with measurable cervical cancer. Six (46%) have had a complete response 
for 6+, 7, 11, 14, 15, and 21 months. Four (30%) have had a partial response for 1, 6, 
10, and 11 months. Two patients (15%) have had stable disease for 6 and 11 months. Only 
one patient failed to respond to this combination. In six of these patients, the measurable 
mass was located in a previously radiated area. This combination was well tolerated with 
only three instances of severe toxicity. No irreversible renal dysfunction was seen in any 
patient. Q 1984 Academic Press, Inc. 
The treatment of cervical cancer has, for the most part, been successful. This 
is due to its propensity to remain confined to the pelvis. However, in those 
patients where it has spread beyond the confines of the pelvis or it persists in 
spite of maximal radiological and surgical therapy, the therapeutic thrust must 
fall to chemotherapy. Numerous agents have been tested in this tumor system, 
but none have demonstrated significant activity [l-5]. 
Preliminary data from the University of Michigan suggest that the combination 
of cisplatin and dichloromethotrexate has exceptional activity against this neoplasm. 
This has been accomplished with a low toxicity rate seldom seen in combinations 
used against cervical cancer. 
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METHODS AND MATERIALS 
Patients included in this study were required to have (1) pathologically confirmed 
cervical cancer not amenable to any surgical or radiological therapy; (2) measurable 
disease; (3) no prior treatment with any chemotherapeutic agent; (4) normal 
function of the bone marrow, liver, and kidneys; and (5) signed informed consent. 
Fourteen patients met these criteria and were included in the study. Basic char- 
acteristics of this group are seen in Table 1. There was an even distribution of 
initial stage seen in this group (Table 2). The site of recurrent measurable disease 
was found in the pelvis, abdomen, or lungs (Table 3). Measurable disease was 
followed by pelvic exam, appropriate X rays, and/or CT scans. In the case of 
pelvic disease, six patients had previously received in excess of 5000 rad to the 
lesion under treatment. 
Cis-Diamminedichloroplatinum II (cisplatin) (NSC-119875) was administered 
intravenously every 4 weeks at a dose of 60 mg/m* over 2 hr. Various antiemetics 
were given in conjunction with this infusion to aid in the control of nausea and 
vomiting. Following completion of this infusion, a 24-hr period of intravenous 
hydration ensued. 
3’,5’-Dichloro-4-amino-4-deoxy-N’O-methylpteroyl-glutamatic acid (dichloro- 
methotrexate) (NSC-29630), supplied by the National Cancer Institute (Bethesda, 
Md.), was given intravenously on a weekly dose-seeking schedule. It was started 
at a dose of 300 mg/m’ and increased by 100 mg/m’ each week until toxicity 
developed. In most cases, the final dose was 600 mg/m’. 
The objective response to this regimen was assigned according to the standard 
definitions: complete remission (CR&disappearance of all clinical evidence of 
tumor on physical examination or X-ray evaluation for greater than 1 month; 
partial remission (PR)--50% or greater decrease by physical or radiological ex- 
amination in the sum of the products of the perpendicular diameters of all measurable 
lesions for greater than 1 month; stabilization (STAB&SO% decrease in measurable 
disease for greater than 2 months; and progression (PROG)-any increase in 
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One patient died of disease after only one course of drug, leaving 13 evaluable 
patients. In the 13 evaluable patients CR was seen in 6 (46%), PR in 4 (30%), 
STAB in 2 (15%), and PROG in only one (8%). When the individual response 
groups are examined, the length of response for the CR group averaged 12.3 + 
months, while survival averaged 18.8+ months. In the PR group, these figures 
are 7 and 11.5 + months, respectively. Of the 10 responders, 7 are alive with 
disease, 2 have died of disease, and one died while in CR. 
These results were obtained with minimal major toxicity. Since a dose-seeking 
schedule was used for the dichloromethotrexate, all patients developed some 
toxicity. In most cases this was a self-limited stomatitis. Once the drug’s main- 
tenance dose was established, no significant toxicity was seen in the majority 
of patients. Severe toxicity was seen in only four cases. Two women experienced 
neurotoxicity with ataxia developing. A complete workup of both suggested that 
the toxicity was secondary to platinum. Both showed nearly complete resolution 
of symptoms when platinum exposure was stopped. A third woman experienced 
one episode of pancytopenia (WBC < 1000, platelets < 25,000) which resolved 
when drug administration was suspended. She was restarted at a lower dose and 
experienced no additional toxicity. A fourth woman developed severe throm- 
bocytopenia, a skin rash and cardiovascular collapse. She represents a drug- 
related death. No woman showed any severe renal damange resulting from the 
treatment regimen. 
DISCUSSION 
Two of the most active chemotherapeutic agents against cervical cancer are 
methotrexate [3] and cisplatin [6]. The combination of these two drugs has 
resulted in intolerably severe methotrexate toxicity which has been attributed 
to impaired renal clearance often resulting from cisplatin toxicity [7]. However, 
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dichloromethotrexate, a dihalogenated analog of methotrexate, is an active antifolate 
and is excreted more by biliary than by urinary routes, therefore, allowing 
potential combination with cisplatin in full doses. It was this lack of a common 
excretory pathway that suggested the potential success of this two drug regimen 
against cervical cancer. 
This preliminary work suggests that squamous cell carcinoma of the cervix is 
quite sensitive to the combination of cisplatin and dichloromethotrexate. In addition, 
this combination seems to be able to maintain this response and results in a 
significant increase in the length of survival. This level of response is even seen 
in those cases when the recurrent malignancy is located in an area previously 
treated with radiation thereapy. More importantly, this success is obtained with 
few untoward side effects. Most women have been able to maintain their normal 
activities; thus, both survival and quality of life are improved. 
One of the disadvantages of this combination is the presence of nausea and 
vomiting and the prolonged hydration time associated with cisplatin. In view of 
the fact the average woman shows a maximal response after three to four cycles 
of drug, it would be of interest to see if a remission could be induced with this 
combination of drugs and maintained with only dichloromethotrexate. Such an 
approach would minimize the untoward effects of cisplatin. This was found to 
be a successful program in the two women who could not continue to receive 
cisplatin because of neurotoxicity. 
At the present time work is underway to test this combination in a larger 
group of women in an effort to confirm these highly encouraging preliminary 
results. 
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